Quest Launches 34-Gene Cancer Dx with Plans for Expanded Panel in 2015; Collaborating with MSKCC | GenomeWeb

NEW YORK (GenomeWeb) -- Quest Diagnostics has launched a next-generation sequencing-based 34-gene panel called OncoVantage and plans to collaborate with Memorial Sloan-Kettering Cancer Center for clinical annotation of the test, Quest said this week.

In addition, Quest will collaborate with Memorial Sloan-Kettering to develop a larger panel that will likely include hundreds of cancer-related genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.